Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13,155,511
-
Total 13F shares
-
7,530,520
-
Share change
-
+800,251
-
Total reported value
-
$55,951,607
-
Price per share
-
$7.43
-
Number of holders
-
33
-
Value change
-
+$4,829,810
-
Number of buys
-
15
-
Number of sells
-
8
Institutional Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q4 2024
As of 31 Dec 2024,
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,530,520 shares.
The largest 10 holders included
BVF INC/IL, Ikarian Capital, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Deep Track Capital, LP, Affinity Asset Advisors, LLC, TCG Crossover Management, LLC, COMMODORE CAPITAL LP, VANGUARD GROUP INC, and BOOTHBAY FUND MANAGEMENT, LLC.
This page lists
33
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.